A New Safety Approach Allowing Reversible Control of CAR T Cell Responses

Résumé fourni par la source

Adoptive immunotherapy involving the genetic-modification of allogeneic or autologous T cells expressing chimeric antigen receptors (CARs) targeting tumor-associated antigens has enabled the transfer of a large number of tumor-specific T cells into patients. Toxicities can occur in patients and are currently managed by immunosuppressive drugs such as corticosteroids and the anti-interleukin-6 (IL-6) receptor antibody, tocilizumab. However, these current treatments compromise the long-term activity of CAR T cells, necessitating a real clinical need for development of better strategies that enable the reversible functional control of CAR T cells.